CAR-T细胞治疗难治/复发急性T淋巴细胞白血病的临床进展
Clinical Progress of CAR-T Cell Therapy for Refractory/Relapsed Acute T Lymphoblastic Leukemia
DOI: 10.12677/acm.2025.153664, PDF,   
作者: 梁明佳, 沈 燕：重庆医科大学附属第二医院血液内科，重庆
关键词: CAR-T细胞疗法；急性淋巴细胞白血病；治疗；CAR-T Cell Therapy； Acute Lymphoblastic Leukemia； Treatment
摘要: 急性T淋巴细胞白血病(T-ALL)起源于未成熟的胸腺细胞，患者的总体预后较急性B淋巴细胞白血病(B-ALL)患者差，生存时间短，尤其难治/复发T-ALL (R/R T-ALL)。虽然新型化疗药物、靶向治疗等治疗方案使该类患者的预后得到了一定程度的改善，但患者的获益仍有限。随着肿瘤免疫治疗时代的到来，嵌合抗原受体T细胞(CAR-T)疗法引入了血液肿瘤的治疗，一定程度上改善了R/R T-ALL患者的预后，本文就CAR-T细胞治疗R/R T-ALL的进展进行综述，以探讨其可行性及潜能。
Abstract: T cell acute lymphoblastic leukemia (T-ALL) originates from immature thymocytes, and the overall prognosis for patients is poorer compared to those with acute B-lymphoblastic leukemia (B-ALL), with shorter survival times, especially in cases of refractory or relapsed T-ALL (R/R T-ALL). Although novel chemotherapeutic agents and targeted therapies have improved the prognosis for these patients to some extent, the benefits remain limited. With the advent of the era of tumor immunotherapy, chimeric antigen receptor T-cell (CAR-T) therapy has been introduced into the treatment of hematologic malignancies, which has improved the prognosis of R/R T-ALL patients to a certain extent. This article reviews the progress of CAR-T cell therapy for R/R T-ALL, so as to explore this therapy’s feasibility and potential.
文章引用：梁明佳, 沈燕. CAR-T细胞治疗难治/复发急性T淋巴细胞白血病的临床进展[J]. 临床医学进展, 2025, 15(3): 676-685. https://doi.org/10.12677/acm.2025.153664

参考文献

[1] Karrman, K. and Johansson, B. (2016) Pediatric T‐Cell Acute Lymphoblastic Leukemia. Genes, Chromosomes and Cancer, 56, 89-116. [Google Scholar] [CrossRef] [PubMed]
[2] Litzow, M.R. and Ferrando, A.A. (2015) How I Treat T-Cell Acute Lymphoblastic Leukemia in Adults. Blood, 126, 833-841. [Google Scholar] [CrossRef] [PubMed]
[3] Mak, V., Hamm, J., Chhanabhai, M., Shenkier, T., Klasa, R., Sehn, L.H., et al. (2013) Survival of Patients with Peripheral T-Cell Lymphoma after First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. Journal of Clinical Oncology, 31, 1970-1976. [Google Scholar] [CrossRef] [PubMed]
[4] Shah, N.N., Lee, D.W., Yates, B., Yuan, C.M., Shalabi, H., Martin, S., et al. (2021) Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults with B-All. Journal of Clinical Oncology, 39, 1650-1659. [Google Scholar] [CrossRef] [PubMed]
[5] Gu, R., Liu, F., Zou, D., Xu, Y., Lu, Y., Liu, B., et al. (2020) Efficacy and Safety of CD19 CAR T Constructed with a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Hematology & Oncology, 13, Article No. 122. [Google Scholar] [CrossRef] [PubMed]
[6] Roddie, C., Lekakis, L.J., Marzolini, M.A.V., Ramakrishnan, A., Zhang, Y., Hu, Y., et al. (2023) Dual Targeting of CD19 and CD22 with Bicistronic CAR-T Cells in Patients with Relapsed/refractory Large B Cell Lymphoma. Blood, 141, 2470-2482. [Google Scholar] [CrossRef] [PubMed]
[7] Jess, J., Yates, B., Dulau-Florea, A., Parker, K., Inglefield, J., Lichtenstein, D., et al. (2023) CD22 CAR T-Cell Associated Hematologic Toxicities, Endothelial Activation and Relationship to Neurotoxicity. Journal for ImmunoTherapy of Cancer, 11, e005898. [Google Scholar] [CrossRef] [PubMed]
[8] Fang, K.K., Lee, J.B. and Zhang, L. (2022) Adoptive Cell Therapy for T-Cell Malignancies. Cancers, 15, Article 94. [Google Scholar] [CrossRef] [PubMed]
[9] Alcantara, M., Tesio, M., June, C.H. and Houot, R. (2018) CAR T-Cells for T-Cell Malignancies: Challenges in Distinguishing between Therapeutic, Normal, and Neoplastic T-Cells. Leukemia, 32, 2307-2315. [Google Scholar] [CrossRef] [PubMed]
[10] Png, Y.T., Vinanica, N., Kamiya, T., Shimasaki, N., Coustan-Smith, E. and Campana, D. (2017) Blockade of CD7 Expression in T Cells for Effective Chimeric Antigen Receptor Targeting of T-Cell Malignancies. Blood Advances, 1, 2348-2360. [Google Scholar] [CrossRef] [PubMed]
[11] Lu, P., Liu, Y., Yang, J., Zhang, X., Yang, X., Wang, H., et al. (2022) Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-In-Human Phase I Clinical Trial. Blood, 140, 321-334. [Google Scholar] [CrossRef] [PubMed]
[12] Cooper, M.L., Choi, J., Staser, K., Ritchey, J.K., Devenport, J.M., Eckardt, K., et al. (2018) An “Off-the-Shelf” Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies. Leukemia, 32, 1970-1983. [Google Scholar] [CrossRef] [PubMed]
[13] Ye, J., Jia, Y., Tuhin, I.J., Tan, J., Monty, M.A., Xu, N., et al. (2022) Feasibility Study of a Novel Preparation Strategy for Anti-CD7 CAR-T Cells with a Recombinant Anti-CD7 Blocking Antibody. Molecular Therapy—Oncolytics, 24, 719-728. [Google Scholar] [CrossRef] [PubMed]
[14] Wei, W., Ma, H., Yang, D., Sun, B., Tang, J., Zhu, Y., et al. (2023) SECTM1-Based CAR T Cells Enriched with CD7-Low/Negative Subsets Exhibit Efficacy in CD7-Positive Malignancies. Blood Advances, 7, 2941-2951. [Google Scholar] [CrossRef] [PubMed]
[15] Hu, Y., Zhou, Y., Zhang, M., Zhao, H., Wei, G., Ge, W., et al. (2022) Genetically Modified CD7-Targeting Allogeneic CAR-T Cell Therapy with Enhanced Efficacy for Relapsed/Refractory CD7-Positive Hematological Malignancies: A Phase I Clinical Study. Cell Research, 32, 995-1007. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, M., Chen, D., Fu, X., Meng, H., Nan, F., Sun, Z., et al. (2022) Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-Cell Therapy for Patients with Relapsed and Refractory T-Cell Acute Lymphoblastic Leukemia/lymphoma. Clinical Cancer Research, 28, 2830-2843. [Google Scholar] [CrossRef] [PubMed]
[17] Pan, J., Tan, Y., Wang, G., Deng, B., Ling, Z., Song, W., et al. (2021) Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. Journal of Clinical Oncology, 39, 3340-3351. [Google Scholar] [CrossRef] [PubMed]
[18] Watanabe, N., Mo, F., Zheng, R., Ma, R., Bray, V.C., van Leeuwen, D.G., et al. (2023) Feasibility and Preclinical Efficacy of CD7-Unedited CD7 CAR T Cells for T Cell Malignancies. Molecular Therapy, 31, 24-34. [Google Scholar] [CrossRef] [PubMed]
[19] Pan, J., Tan, Y., Wang, G., Deng, B., Ling, Z., Song, W., et al. (2022) Updated Efficacy and Safety Report of a Phase I Trial of Donor-Derived CD7 CAR T Cells for T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 40, 7023-7023. [Google Scholar] [CrossRef] 
[20] Zhang, X., Yang, J., Li, J., Qiu, L., Li, J. and Lu, P. (2022) Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy. Blood, 140, 2369-2370. [Google Scholar] [CrossRef] 
[21] Ghobadi, A., Aldoss, I., Maude, S., Bhojwani, D., Wayne, A., Bajel, A., et al. (2024) Anti-CD7 Allogeneic WU-CART-007 in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Phase 1/2 Trial. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, Y., Li, C., Du, M., Jiang, H., Luo, W., Tang, L., et al. (2023) Allogenic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T-Cell Malignancies. Blood Cancer Journal, 13, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[23] Li, Z., Zheng, Q., Yang, K., Xu, T., Wang, L., Wang, X., et al. (2025) CD7 CART Therapy Bridging Allo-HSCT Remarkably Improves Long-Term DFS in Refractory/relapsed T-ALL/LBL. Transplantation and Cellular Therapy, 31, 73.e1-73.e11. [Google Scholar] [CrossRef] [PubMed]
[24] Campana, D., van Dongen, J., Mehta, A., Coustan-Smith, E., Wolvers-Tettero, I., Ganeshaguru, K., et al. (1991) Stages of T-Cell Receptor Protein Expression in T-Cell Acute Lymphoblastic Leukemia. Blood, 77, 1546-1554. [Google Scholar] [CrossRef] 
[25] Pui, C., Behm, F. and Crist, W. (1993) Clinical and Biologic Relevance of Immunologic Marker Studies in Childhood Acute Lymphoblastic Leukemia. Blood, 82, 343-362. [Google Scholar] [CrossRef] 
[26] Pan, J., Tan, Y., Shan, L., Seery, S., Deng, B., Ling, Z., et al. (2024) Allogeneic CD5-Specific CAR-T Therapy for Relapsed/Refractory T-ALL: A Phase 1 Trial. Nature Medicine, 31, 126-136. [Google Scholar] [CrossRef] [PubMed]
[27] Sánchez-Martínez, D., Baroni, M.L., Gutierrez-Agüera, F., Roca-Ho, H., Blanch-Lombarte, O., González-García, S., et al. (2019) Fratricide-Resistant CD1A-Specific CAR T Cells for the Treatment of Cortical T-Cell Acute Lymphoblastic Leukemia. Blood, 133, 2291-2304. [Google Scholar] [CrossRef] [PubMed]
[28] Carrera Silva, E.A., Nowak, W., Tessone, L., Olexen, C.M., Ortiz Wilczyñski, J.M., Estecho, I.G., et al. (2017) CD207+CD1a+ Cells Circulate in Pediatric Patients with Active Langerhans Cell Histiocytosis. Blood, 130, 1898-1902. [Google Scholar] [CrossRef] [PubMed]
[29] Bechan, G.I., Lee, D.W., Zajonc, D.M., Heckel, D., Xian, R., Throsby, M., et al. (2012) Phage Display Generation of a Novel Human Anti‐CD1A Monoclonal Antibody with Potent Cytolytic Activity. British Journal of Haematology, 159, 299-310. [Google Scholar] [CrossRef] [PubMed]
[30] Cernadas, M., Lu, J., Watts, G. and Brenner, M.B. (2008) Cd1a Expression Defines an Interleukin-12 Producing Population of Human Dendritic Cells. Clinical and Experimental Immunology, 155, 523-533. [Google Scholar] [CrossRef] [PubMed]
[31] Maciocia, P.M., Wawrzyniecka, P.A., Maciocia, N.C., Burley, A., Karpanasamy, T., Devereaux, S., et al. (2022) Anti-CCR9 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia. Blood, 140, 25-37. [Google Scholar] [CrossRef] [PubMed]
[32] Lin, P., Owens, R., Tricot, G. and Wilson, C.S. (2004) Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma. American Journal of Clinical Pathology, 121, 482-488. [Google Scholar] [CrossRef] [PubMed]
[33] Laubach, J.P., Tai, Y., Richardson, P.G. and Anderson, K.C. (2014) Daratumumab Granted Breakthrough Drug Status. Expert Opinion on Investigational Drugs, 23, 445-452. [Google Scholar] [CrossRef] [PubMed]
[34] Jalal, S.D., Al‐Allawi, N.A.S. and Al Doski, A.A.S. (2017) Immunophenotypic Aberrancies in Acute Lymphoblastic Leukemia from 282 Iraqi Patients. International Journal of Laboratory Hematology, 39, 625-632. [Google Scholar] [CrossRef] [PubMed]
[35] Deckert, J., Wetzel, M., Bartle, L.M., Skaletskaya, A., Goldmacher, V.S., Vallée, F., et al. (2014) SAR650984, a Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies. Clinical Cancer Research, 20, 4574-4583. [Google Scholar] [CrossRef] [PubMed]
[36] Glisovic-Aplenc, T., Diorio, C., Chukinas, J.A., Veliz, K., Shestova, O., Shen, F., et al. (2023) CD38 as a Pan-Hematologic Target for Chimeric Antigen Receptor T Cells. Blood Advances, 7, 4418-4430. [Google Scholar] [CrossRef] [PubMed]
[37] Wang, X., Yu, X., Li, W., Neeli, P., Liu, M., Li, L., et al. (2022) Expanding Anti-CD38 Immunotherapy for Lymphoid Malignancies. Journal of Experimental & Clinical Cancer Research, 41, Article No. 210. [Google Scholar] [CrossRef] [PubMed]
[38] Cox, C.V., Diamanti, P., Moppett, J.P. and Blair, A. (2016) Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia. PLOS ONE, 11, e0165210. [Google Scholar] [CrossRef] [PubMed]
[39] Dworzak, M.N., Fröschl, G., Printz, D., Zen, L.D., Gaipa, G., Ratei, R., et al. (2004) CD99 Expression in T-Lineage ALL: Implications for Flow Cytometric Detection of Minimal Residual Disease. Leukemia, 18, 703-708. [Google Scholar] [CrossRef] [PubMed]
[40] Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., et al. (2021) CAR T Cells Targeting CD99 as an Approach to Eradicate T-Cell Acute Lymphoblastic Leukemia without Normal Blood Cells Toxicity. Journal of Hematology & Oncology, 14, Article No. 162. [Google Scholar] [CrossRef] [PubMed]
[41] Mullard, A. (2021) FDA Approves Fourth CAR-T Cell Therapy. Nature Reviews Drug Discovery, 20, 166-166. [Google Scholar] [CrossRef] [PubMed]
[42] Pinz, K., Liu, H., Golightly, M., Jares, A., Lan, F., Zieve, G.W., et al. (2015) Preclinical Targeting of Human T-Cell Malignancies Using CD4-Specific Chimeric Antigen Receptor (CAR)-Engineered T Cells. Leukemia, 30, 701-707. [Google Scholar] [CrossRef] [PubMed]
[43] Maciocia, P.M., Wawrzyniecka, P.A., Philip, B., Ricciardelli, I., Akarca, A.U., Onuoha, S.C., et al. (2017) Targeting the T Cell Receptor Β-Chain Constant Region for Immunotherapy of T Cell Malignancies. Nature Medicine, 23, 1416-1423. [Google Scholar] [CrossRef] [PubMed]
[44] Zheng, N., Zhao, X., Wei, D., Miao, J., Liu, Z., Yong, Y., et al. (2022) CD147-Specific Chimeric Antigen Receptor T Cells Effectively Inhibit T Cell Acute Lymphoblastic Leukemia. Cancer Letters, 542, 215762. [Google Scholar] [CrossRef] [PubMed]
[45] Raulet, D.H. (2003) Roles of the NKG2D Immunoreceptor and Its Ligands. Nature Reviews Immunology, 3, 781-790. [Google Scholar] [CrossRef] [PubMed]
[46] Torelli, G.F., Peragine, N., Raponi, S., Pagliara, D., De Propris, M.S., Vitale, A., et al. (2014) Recognition of Adult and Pediatric Acute Lymphoblastic Leukemia Blasts by Natural Killer Cells. Haematologica, 99, 1248-1254. [Google Scholar] [CrossRef] [PubMed]
[47] Schlegel, P., Ditthard, K., Lang, P., Mezger, M., Michaelis, S., Handgretinger, R., et al. (2015) NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML. Journal of Immunology Research, 2015, Article ID: 473175. [Google Scholar] [CrossRef] [PubMed]
[48] Driouk, L., Gicobi, J.K., Kamihara, Y., Rutherford, K., Dranoff, G., Ritz, J., et al. (2020) Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Frontiers in Immunology, 11, Article 58028. [Google Scholar] [CrossRef] [PubMed]
[49] Sallman, D.A., Brayer, J., Sagatys, E.M., Lonez, C., Breman, E., Agaugué, S., et al. (2018) NKG2D-BASED Chimeric Antigen Receptor Therapy Induced Remission in a Relapsed/refractory Acute Myeloid Leukemia Patient. Haematologica, 103, e424-e426. [Google Scholar] [CrossRef] [PubMed]
[50] Ibáñez-Navarro, M., Fernández, A., Escudero, A., Esteso, G., Campos-Silva, C., Navarro-Aguadero, M.Á., et al. (2023) NKG2D-CAR Memory T Cells Target Pediatric T-Cell Acute Lymphoblastic Leukemia in Vitro and in Vivo but Fail to Eliminate Leukemia Initiating Cells. Frontiers in Immunology, 14, Article 1187665. [Google Scholar] [CrossRef] [PubMed]
[51] Binder, C., Cvetkovski, F., Sellberg, F., Berg, S., Paternina Visbal, H., Sachs, D.H., et al. (2020) CD2 Immunobiology. Frontiers in Immunology, 11, Article 1090. [Google Scholar] [CrossRef] [PubMed]
[52] Dustin, M.L. and Springer, T.A. (1991) Role of Lymphocyte Adhesion Receptors in Transient Interactions and Cell Locomotion. Annual Review of Immunology, 9, 27-66. [Google Scholar] [CrossRef] [PubMed]
[53] Gorczyca, W., Weisberger, J., Liu, Z., Tsang, P., Hossein, M., Wu, C.D., et al. (2002) An Approach to Diagnosis of T‐cell Lymphoproliferative Disorders by Flow Cytometry. Cytometry, 50, 177-190. [Google Scholar] [CrossRef] [PubMed]
[54] Xiang, J., Devenport, J.M., Carter, A.J., Staser, K.W., Kim, M.Y., O’Neal, J., et al. (2023) An “Off-the-Shelf” CD2 Universal CAR-T Therapy for T-Cell Malignancies. Leukemia, 37, 2448-2456. [Google Scholar] [CrossRef] [PubMed]
[55] DiPersio, J.F., Staser, K. and Cooper, M. (2020) Immunotherapy for T-Cell ALL and T-Cell NHL. Clinical Lymphoma Myeloma and Leukemia, 20, S56-S58. [Google Scholar] [CrossRef] [PubMed]
[56] Noronha, E.P., Marques, L.V.C., Andrade, F.G., Thuler, L.C.S., Terra-Granado, E. and Pombo-de-Oliveira, M.S. (2019) The Profile of Immunophenotype and Genotype Aberrations in Subsets of Pediatric T-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology, 9, Article 316. [Google Scholar] [CrossRef] [PubMed]
[57] Pu, Q., Qiao, J., Liu, Y., Cao, X., Tan, R., Yan, D., et al. (2022) Differential Diagnosis and Identification of Prognostic Markers for Peripheral T-Cell Lymphoma Subtypes Based on Flow Cytometry Immunophenotype Profiles. Frontiers in Immunology, 13, Article 1008695. [Google Scholar] [CrossRef] [PubMed]
[58] Lee, J.B., Kang, H., Fang, L., D'Souza, C., Adeyi, O. and Zhang, L. (2019) Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer. Clinical Cancer Research, 25, 2241-2253. [Google Scholar] [CrossRef] [PubMed]
[59] Fang, K.K., Lee, J., Khatri, I., Na, Y. and Zhang, L. (2023) Targeting T-Cell Malignancies Using Allogeneic Double-Negative CD4-CAR-T Cells. Journal for ImmunoTherapy of Cancer, 11, e007277. [Google Scholar] [CrossRef] [PubMed]
[60] Ma, G., Shen, J., Pinz, K., Wada, M., Park, J., Kim, S., et al. (2019) Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch. Stem Cell Reviews and Reports, 15, 443-447. [Google Scholar] [CrossRef] [PubMed]
[61] Ohkuma, M., Haraguchi, N., Ishii, H., Mimori, K., Tanaka, F., Kim, H.M., et al. (2011) Absence of CD71 Transferrin Receptor Characterizes Human Gastric Adenosquamous Carcinoma Stem Cells. Annals of Surgical Oncology, 19, 1357-1364. [Google Scholar] [CrossRef] [PubMed]
[62] Gu, Z., Wang, H., Xia, J., Yang, Y., Jin, Z., Xu, H., et al. (2015) Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation. Cancer Research, 75, 2211-2221. [Google Scholar] [CrossRef] [PubMed]
[63] Singh, M., Mugler, K., Hailoo, D.W., Burke, S., Nemesure, B., Torkko, K., et al. (2011) Differential Expression of Transferrin Receptor (TFR) in a Spectrum of Normal to Malignant Breast Tissues. Applied Immunohistochemistry & Molecular Morphology, 19, 417-423. [Google Scholar] [CrossRef] [PubMed]
[64] Guo, Z., Zhang, Y., Fu, M., Zhao, L., Wang, Z., Xu, Z., et al. (2021) The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies. Frontiers in Immunology, 12, Article 652924. [Google Scholar] [CrossRef] [PubMed]
[65] Kathpalia, M., Mishra, P., Bajpai, R., Bhurani, D. and Agarwal, N. (2022) Efficacy and Safety of Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. Annals of Hematology, 101, 1655-1666. [Google Scholar] [CrossRef] [PubMed]
[66] Candoni, A., Lazzarotto, D., Ferrara, F., Curti, A., Lussana, F., Papayannidis, C., et al. (2020) Nelarabine as Salvage Therapy and Bridge to Allogeneic Stem Cell Transplant in 118 Adult Patients with Relapsed/Refractory T‐Cell Acute Lymphoblastic Leukemia/lymphoma. A Campus All Study. American Journal of Hematology, 95, 1466-1472. [Google Scholar] [CrossRef] [PubMed]
[67] Gökbuget, N., Basara, N., Baurmann, H., Beck, J., Brüggemann, M., Diedrich, H., et al. (2011) High Single-Drug Activity of Nelarabine in Relapsed T-Lymphoblastic Leukemia/lymphoma Offers Curative Option with Subsequent Stem Cell Transplantation. Blood, 118, 3504-3511. [Google Scholar] [CrossRef] [PubMed]
[68] Feng, L., Li, H., Tang, A., Xu, M. and Wang, S. (2025) Venetoclax and Azacitidine in Combination with Homoharringtonine, Cytarabine, and Aclarubicin for Salvage Therapy of Relapsed/Refractory T Cell Acute Lymphoblastic Leukemia. International Journal of Hematology. [Google Scholar] [CrossRef] [PubMed]
[69] Kong, J.Y., Zong, L.H., Pu, Y., Liu, Y., Kong, X., Li, M.Y., et al. (2023) Clinical Efficacy and Safety of Venetoclax Combined with Multidrug Chemotherapy in the Treatment of 15 Patients with Relapsed or Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia. Chinese Journal of Hematology, 44, 649-653. [Google Scholar] [CrossRef] [PubMed]
[70] Wan, C., Zou, J., Qiao, M., Yin, J., Shen, X., Qiu, Q., et al. (2021) Venetoclax Combined with Azacitidine as an Effective and Safe Salvage Regimen for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Case Series. Leukemia & Lymphoma, 62, 3300-3303. [Google Scholar] [CrossRef] [PubMed]
[71] Rahmat, L.T., Nguyen, A., Abdulhaq, H., Prakash, S., Logan, A.C. and Mannis, G.N. (2018) Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. Case Reports in Hematology, 2018, Article ID: 6092646. [Google Scholar] [CrossRef] [PubMed]
[72] Prejzner, W., Piekoś, O., Bełdzińska, K., Sadowska-Klasa, A., Zarzycka, E., Bieniaszewska, M., et al. (2023) The Role of Daratumumab in Relapsed/Refractory CD38 Positive Acute Leukemias—Case Report on Three Cases with a Literature Review. Frontiers in Oncology, 13, Article 1228481. [Google Scholar] [CrossRef] [PubMed]
[73] Chupradit, K., Muneekaew, S. and Wattanapanitch, M. (2024) Engineered CD147-CAR Macrophages for Enhanced Phagocytosis of Cancers. Cancer Immunology, Immunotherapy, 73, Article No. 170. [Google Scholar] [CrossRef] [PubMed]

为你推荐